Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $251
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. AXSM | 0.00 |
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:
AXSM) with a Equal-Weight and raises the price target from $242 to $251.
